Amytrx Therapeutics Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3, a Promising Anti-Inflammatory Peptide Therapeutic for Atopic Dermatitis
WBTW News13,
NASHVILLE, June 28, 2023 /PRNewswire/ -- Amytrx Therapeutics, an emerging pharmaceutical company specializing in innovative anti…